Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial.

TheraCIM (nimotuzumab) - Daiichi Sankyo, Biocon, Biotech Pharma

http://www.ncbi.nlm.nih.gov/pubmed/42729623

Chunyan Chen; Lin Wang; Linquan Tang; Liting Liu; Nian Lu; Shuhui Lv; Shuiqing He; Wei-Xin Bei; Yan-Qun Xiang; Yanfang Ye; Ze-Yu Zhao

Sep 13, 2026